CompletedPhase 1NCT03636477

A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102

Studying Glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Alaunos Therapeutics
Principal Investigator
Jaymes Holland, BC-HIS
Alaunos Therapeutics
Intervention
Ad-RTS-hIL-12(biological)
Enrollment
21 target
Eligibility
18-75 years · All sexes
Timeline
20182021

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03636477 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma

← Back to all trials